由Streptomyces sp.产生的新的抗疟疾伊罗米辛类似物. RBL-0292 这是一本小说
So-Ichiro Kimura1, Yoshihiro Watanabe1,2, Shiori Shibasaki2
1Graduate School of Infection Control Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan.
The Journal of antibiotics
|March 4, 2024
概括
从Streptomyces细菌中鉴定出了两种新的抗疟疾化合物,即甲和乙. 这些化合物对Plasmodium falciparum疟疾菌株表现出中度活性.
科学领域:
- 自然产品化学 自然产品化学
- 药用化学 医学化学
- 微生物学 微生物学
背景情况:
- 疟疾仍然是一个重大的全球卫生挑战,需要发现新的抗疟疾药物.
- 动菌体是各种具有治疗潜力的生物活性天然产品的丰富来源.
- 抗药性Plasmodium falciparum菌株的出现强调了迫切需要新型抗疟疾药物的需求.
研究的目的:
- 发现和描述来自actinomycete微生物的新抗疟疾化合物.
- 阐明从Streptomyces sp.中分离出来的新型化合物的化学结构. RBL-0292.2. 这是一个很大的问题.
- 评估隔离的化合物在体外抗疟疾活性,以对抗Plasmodium falciparum.
主要方法:
- 隔离和种植的行为菌株菌株Streptomyces sp. 的菌株. RBL-0292从土壤样本中获得的数据.
- 从培养的actinomycete中提取和净化二次代谢产物.
- 使用质谱 (MS) 和核磁共振 (NMR) 分析来阐明净化化合物的结构.
- 在体外抗疟疾活性测定对氨酸敏感和氨酸耐药的Plasmodium falciparum菌株.
主要成果:
- 两种新的抗疟疾化合物,前尼尔皮里顿A (1) 和B (2) 已成功分离和鉴定.
- 化合物1和2的结构被确定为具有α-pyridone环的新型iromycin类似物.
- 化合物1和2在体外表现出中度的抗疟疾活性,IC50值在80.7至106.7μM之间对敏感和耐药的Plasmodium falciparum菌株.
结论:
- 这种动态菌株Streptomyces sp. RBL-0292产生具有抗疟疾功能的含α-皮里的新型化合物.
- 甲甲和乙代表了一类新的潜在抗疟疾药物.
- 需要进一步的研究来优化这些化合物以提高疗效,并了解它们的作用机制.
相关概念视频
Microorganisms in Medicine and Therapeutics
1.4K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.4K
Production of Antibiotics
265
Penicillin, one of the earliest and most widely used antibiotics, is produced industrially by the filamentous fungus Penicillium chrysogenum. Large stirred-tank bioreactors ranging from tens to hundreds of thousands of liters maintain tightly controlled temperature, pH, and dissolved oxygen conditions to support fungal metabolism and maximize antibiotic yield. Penicillin is a secondary metabolite, synthesized primarily during the stationary growth phase, which requires a carefully managed...
265
Production of Pharmaceuticals
94
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under...
94
iChip
105
The cultivation of environmental microorganisms has long been hindered by the inability to replicate complex native conditions in vitro. The isolation chip (iChip) addresses this limitation by facilitating the growth of previously uncultivable microorganisms through in situ incubation. Designed for high-throughput microbial cultivation, the iChip comprises hundreds of microchambers, each capable of housing a single microbial cell. These microchambers are loaded with a mixture of molten agar and...
105
Inhibitors of Bacterial Protein Synthesis
106
Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
106
Clinical Significance of Antibiotic Resistance
90
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within...
90


